CYTK Cytokinetics, Incorporated

15.95
+0  (3%)
Previous Close 15.55
Open 15.50
Price To book 6.70
Market Cap 665.58M
Shares 41,729,000
Volume 1,153,217
Short Ratio 7.13
Av. Daily Volume 520,827

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated January 2016. Data are due 1H 2017. Second cohort open to enrollment as of March 29, 2017.
CK-2127107
Spinal muscular atrophy (SMA)
Phase 3 commencement announced December 1, 2016.
Omecamtiv mecarbil GALACTIC-HF
Acute heart failure
Phase 3 data are due 4Q 2017.
Tirasemtiv - VITALITY
Amyotrophic lateral sclerosis (ALS)
Phase 2 initiated June 2016. Enrollment to be completed in 2017.
CK-2127107
Chronic obstructive pulmonary disease (COPD)

Latest News

  1. ETFs with exposure to Cytokinetics, Inc. : April 24, 2017
  2. Cytokinetics Added to S&P SmallCap 600
  3. Cytokinetics, Inc. – Value Analysis (NASDAQ:CYTK) : April 20, 2017
  4. Cytokinetics, Inc.: Leads amongst peers with strong fundamentals
  5. Cytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : April 19, 2017
  6. Biotech Industry Outperforming Major Indexes in 2017: Today's Research Reports on Arena Pharmaceuticals and Cytokinetics
  7. Why Cytokinetics, Inc. Jumped Higher Today
  8. Gigamon, CBL & Associates Properties and Cytokinetics Set to Join S&P SmallCap 600
  9. Cytokinetics to Announce First Quarter Results on April 27, 2017
  10. Cytokinetics, Inc. breached its 50 day moving average in a Bearish Manner : CYTK-US : April 6, 2017
  11. Cytokinetics to Present at the 16th Annual Needham Healthcare Conference
  12. Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients With Spinal Muscular Atrophy
  13. Origent Data Sciences and Cytokinetics Advance Collaboration Intended to Validate Predictive Analytics Model in ALS
  14. Cytokinetics SMA Drug Did Well in Early Study
  15. Cytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scientific Conference
  16. Cytokinetics Announces Additional Results From COSMIC-HF Presented at ACC.17
  17. Key Indexes Rise, Steel Stocks Up Before Fed News; A Curious Trend In IBD 50
  18. Biotech Firm's Stock Options Complicate Its Valuation
  19. 7 Stocks Trending Up With Monster Volume
  20. Cytokinetics Announces Presentation of Additional Results from COSMIC-HF at ACC.17

SEC Filings

  1. 8-K - Current report 17739379
  2. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17730826
  3. DEF 14A - Other definitive proxy statements 17730788
  4. 8-K - Current report 17720656
  5. 8-K - Current report 17708148
  6. 8-K - Current report 17705689
  7. 8-K - Current report 17700793
  8. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17668942
  9. 8-K - Current report 17659946
  10. 8-K - Current report 17617904